Classic view of this page
Cancer Hotspot Panel
Clinical Genetic Test
Help
offered by
Genome-Nilou Lab
GTR Test Accession: Help GTR000597429.1
CANCERINHERITED DISEASENERVOUS SYSTEM ... View more
Registered in GTR: 2022-03-28
View version history
Last annual review date for the lab: 2024-08-09 LinkOut
At a Glance
Test purpose: Help
Drug Response; Prognostic; Risk Assessment; ...
Conditions (45): Help
Acute myeloid leukemia; Acquired polycythemia vera; Adenomatous polyposis coli, attenuated more...
Genes (34): Help
ABL1 (9q34.12); AKT1 (14q32.33); ALK (2p23.2-23.1); APC (5q22.2); ATM (11q22.3) more...
Methods (1): Help
Molecular Genetics - Sequence analysis of select exons: Next-Generation (NGS)/Massively parallel sequencing (MPS)
Target population: Help
Any person affected by cancer
Clinical validity: Help
Not provided
Clinical utility: Help
Not provided
Ordering Information
Offered by: Help
Genome-Nilou Lab
View lab's website
Test short name: Help
CHP
Manufacturer's name: Help
Ion AmpliSeq™ Cancer Hotspot Panel
Specimen Source: Help
  • Cell-free DNA
  • Isolated DNA
  • Paraffin block
Who can order: Help
  • Genetic Counselor
  • Licensed Physician
Test Order Code: Help
CHP
Lab contact: Help
Shahram Savad, PhD, MD, Lab Director
Contact Policy: Help
Post-test email/phone consultation regarding genetic test results and interpretation is provided to patients/families.
Pre-test email/phone consultation regarding genetic test results and interpretation is provided to patients/families.
Test service: Help
Genetic counseling
Informed consent required: Help
Yes
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
How to Order, Test strategy, Test development
Conditions Help
Total conditions: 45
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 34
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 1
Method Category Help
Test method Help
Instrument
Sequence analysis of select exons
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Ion Torrent Proton
Clinical Information
Test purpose: Help
Drug Response; Prognostic; Risk Assessment; Therapeutic management
Target population: Help
Any person affected by cancer
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
According to ACMG guidelines

Will the lab re-contact the ordering physician if variant interpretation changes? Help
Not provided.
Recommended fields not provided:
Clinical validity, Clinical utility, Are family members with defined clinical status recruited to assess significance of VUS without charge?, Will the lab re-contact the ordering physician if variant interpretation changes?, Is research allowed on the sample after clinical testing is complete?, Sample negative report, Sample positive report
Technical Information
Test Platform:
Ion semiconductor sequencing
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
98% detection rate for 5% variant frequency at positions with average sequencing coverage from 1,000X to 4,000X
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
No
Recommended fields not provided:
Test Confirmation, Assay limitations, Description of internal test validation method, Citations for Analytical validity, PT Provider, Description of PT method, Major CAP category, CAP category, CAP test list
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.